| Computational Drug Discovery Methods | Lifetime | 362 | IN 4 | 98.23 |
| Protein Interaction Studies and Fluorescence Analysis | Lifetime | 193 | IN 20 | 96.45 |
| Cholinesterase and Neurodegenerative Diseases | Lifetime | 438 | IN 7 | 96.87 |
| Enzyme function and inhibition | Lifetime | 214 | IN 2 | 95.78 |
| Enzyme Structure and Function | Lifetime | 954 | IN 6 | 96.62 |
| Protein Structure and Dynamics | Lifetime | 989 | IN 9 | 96.72 |
| Nigella sativa pharmacological applications | Lifetime | 133 | IN 13 | 90.66 |
| 14-3-3 protein interactions | Lifetime | 802 | IN 13 | 78.54 |
| Synthesis and bioactivity of alkaloids | Lifetime | 860 | IN 75 | 68.52 |
| Computational Drug Discovery Methods | 2021-2025 | 38 | IN 3 | 98.85 |
| Cholinesterase and Neurodegenerative Diseases | 2021-2025 | 17 | IN 3 | 97.92 |
| Cancer, Hypoxia, and Metabolism | 2021-2025 | 93 | IN 1 | 97.04 |
| Bioactive Compounds and Antitumor Agents | 2021-2025 | 15 | IN 1 | 96.73 |
| Cancer Mechanisms and Therapy | 2021-2025 | 49 | IN 1 | 96.44 |
| Cancer-related Molecular Pathways | 2021-2025 | 66 | IN 3 | 95.26 |
| Alzheimer's disease research and treatments | 2021-2025 | 259 | IN 4 | 97.13 |
| Cancer therapeutics and mechanisms | 2021-2025 | 73 | IN 8 | 94.43 |
| Nigella sativa pharmacological applications | 2021-2025 | 12 | IN 3 | 91.03 |
| Drug Transport and Resistance Mechanisms | 2021-2025 | 105 | IN 4 | 93.69 |
| Mitochondrial Function and Pathology | 2021-2025 | 493 | IN 11 | 90.50 |
| ATP Synthase and ATPases Research | 2021-2025 | 85 | IN 2 | 89.24 |
| Heterocyclic Compound Synthesis and Bioactivity | 2021-2025 | 504 | IN 96 | 93.30 |
| PI3K/AKT/mTOR signaling in cancer | 2021-2025 | 128 | IN 2 | 86.75 |
| Medicinal Plants and Neuroprotection | 2021-2025 | 193 | IN 50 | 87.74 |
| Synthesis and bioactivity of alkaloids | 2021-2025 | 17 | IN 3 | 86.49 |
| Ubiquitin and proteasome pathways | 2021-2025 | 555 | IN 4 | 86.44 |
| Protein Interaction Studies and Fluorescence Analysis | 2021-2025 | 101 | IN 23 | 87.42 |
| Pharmacological Effects of Natural Compounds | 2021-2025 | 514 | IN 19 | 84.90 |
| Protein Kinase Regulation and GTPase Signaling | 2021-2025 | 83 | IN 3 | 83.73 |
| Sphingolipid Metabolism and Signaling | 2021-2025 | 139 | IN 2 | 84.53 |
| Natural Antidiabetic Agents Studies | 2021-2025 | 533 | IN 80 | 84.94 |
| Enzyme function and inhibition | 2021-2025 | 88 | IN 4 | 86.38 |
| Protein Structure and Dynamics | 2021-2025 | 682 | IN 16 | 85.53 |
| Microtubule and mitosis dynamics | 2021-2025 | 364 | IN 4 | 80.94 |
| Biochemical and Molecular Research | 2021-2025 | 321 | IN 15 | 78.16 |
| Cell death mechanisms and regulation | 2021-2025 | 164 | IN 2 | 77.25 |
| Melanoma and MAPK Pathways | 2021-2025 | 438 | IN 3 | 80.95 |
| Enzyme Structure and Function | 2021-2025 | 544 | IN 7 | 79.71 |
| Flavonoids in Medical Research | 2021-2025 | 104 | IN 15 | 73.73 |
| Genomics, phytochemicals, and oxidative stress | 2021-2025 | 604 | IN 23 | 75.25 |
| Biochemical effects in animals | 2021-2025 | 586 | IN 14 | 75.62 |
| Biochemical Acid Research Studies | 2021-2025 | 94 | IN 4 | 75.35 |
| NF-κB Signaling Pathways | 2021-2025 | 164 | IN 2 | 68.31 |
| Tea Polyphenols and Effects | 2021-2025 | 759 | IN 14 | 75.12 |
| Quinazolinone synthesis and applications | 2021-2025 | 468 | IN 64 | 67.57 |
| Phytochemical compounds biological activities | 2021-2025 | 481 | IN 29 | 63.03 |
| 14-3-3 protein interactions | 2021-2025 | 95 | IN 6 | 59.83 |
| Genetics, Bioinformatics, and Biomedical Research | 2021-2025 | 441 | IN 26 | 59.86 |
| Diverse Scientific Research Studies | 2021-2025 | 490 | IN 155 | 58.70 |
| Berberine and alkaloids research | 2021-2025 | 366 | IN 31 | 58.23 |
| Hemoglobin structure and function | 2021-2025 | 564 | IN 15 | 45.07 |
